众生药业
(002317)
| 流通市值：111.07亿 | | | 总市值：124.42亿 |
| 流通股本：7.62亿 | | | 总股本：8.53亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 641,123,852.5 | 2,610,550,120.98 | 2,071,278,555.78 | 1,482,289,475.29 |
| 营业收入 | 641,123,852.5 | 2,610,550,120.98 | 2,071,278,555.78 | 1,482,289,475.29 |
| 利息收入 | 0 | 0 | 0 | - |
| 已赚保费 | 0 | 0 | 0 | - |
| 手续费及佣金收入 | 0 | 0 | 0 | - |
| 二、营业总成本 | 564,699,468.91 | 2,295,496,923.31 | 1,744,613,102.75 | 1,230,517,959.43 |
| 营业成本 | 278,952,444.18 | 1,080,875,266.25 | 820,456,295.4 | 567,850,394.25 |
| 利息支出 | 0 | 0 | 0 | - |
| 手续费及佣金支出 | 0 | 0 | 0 | - |
| 退保金 | 0 | 0 | 0 | - |
| 赔付支出净额 | 0 | 0 | 0 | - |
| 提取保险合同准备金净额 | 0 | 0 | 0 | - |
| 保单红利支出 | 0 | 0 | 0 | - |
| 分保费用 | 0 | 0 | 0 | - |
| 税金及附加 | 6,931,422.23 | 24,924,861.82 | 16,490,779.63 | 11,835,070.5 |
| 销售费用 | 213,627,193.97 | 889,897,441.5 | 696,811,016.6 | 507,865,083.42 |
| 管理费用 | 32,986,828.28 | 155,646,170.02 | 112,093,711.53 | 76,077,539.2 |
| 研发费用 | 29,971,407.45 | 127,369,021.12 | 81,119,346.81 | 53,452,972.33 |
| 财务费用 | 2,230,172.8 | 16,784,162.6 | 17,641,952.78 | 13,436,899.73 |
| 其中:利息费用 | 8,523,068.11 | 46,911,917.65 | 35,294,689.34 | 23,382,083.74 |
| 其中:利息收入 | 6,487,063.08 | 30,610,022.03 | 19,201,071.71 | 12,106,281.87 |
| 加:公允价值变动收益 | -25,497,155.37 | -65,230,754.23 | -54,768,168.35 | -50,196,369.54 |
| 加:投资收益 | 7,168,129.28 | 23,528,489.75 | 17,409,406.04 | 12,644,264.58 |
| 净敞口套期收益 | 0 | 0 | 0 | - |
| 汇兑收益 | 0 | 0 | 0 | - |
| 资产处置收益 | 0 | 21,684,431.17 | 21,684,431.17 | 21,676,240.75 |
| 资产减值损失(新) | -1,506,358.31 | -16,746,461.11 | 0 | - |
| 信用减值损失(新) | -532,781.49 | 398,937.31 | -3,870,360.86 | -4,873,329.58 |
| 其他收益 | 3,217,671.73 | 20,042,986.46 | 8,764,139.49 | 3,637,241.94 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 59,273,889.43 | 298,730,827.02 | 315,884,900.52 | 234,659,564.01 |
| 加:营业外收入 | 13,577.21 | 1,192,790.46 | 242,910.22 | 126,213.91 |
| 减:营业外支出 | 170,841.41 | 16,266,738.17 | 1,767,652.92 | 1,433,416.17 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 59,116,625.23 | 283,656,879.31 | 314,360,157.82 | 233,352,361.75 |
| 减:所得税费用 | 10,405,699.02 | 33,755,938.41 | 35,145,189.4 | 21,103,607.92 |
| 六、净利润 | 48,710,926.21 | 249,900,940.9 | 279,214,968.42 | 212,248,753.83 |
| 持续经营净利润 | 48,710,926.21 | 249,900,940.9 | 279,214,968.42 | 212,248,753.83 |
| 终止经营净利润 | 0 | 0 | 0 | - |
| 归属于母公司股东的净利润 | 51,293,866.37 | 263,273,179.73 | 279,495,705.55 | 208,550,306.83 |
| 少数股东损益 | -2,582,940.16 | -13,372,238.83 | -280,737.13 | 3,698,447 |
| (一)基本每股收益 | 0.06 | 0.32 | 0.34 | 0.26 |
| (二)稀释每股收益 | 0.06 | 0.32 | 0.34 | 0.26 |
| 八、其他综合收益 | 605,085.13 | 2,913,314.44 | 3,741,272.62 | 1,329,105.26 |
| 归属于母公司股东的其他综合收益 | 605,085.13 | 2,913,314.44 | 3,741,272.62 | 1,329,105.26 |
| 九、综合收益总额 | 49,316,011.34 | 252,814,255.34 | 282,956,241.04 | 213,577,859.09 |
| 归属于母公司股东的综合收益总额 | 51,898,951.5 | 266,186,494.17 | 283,236,978.17 | 209,879,412.09 |
| 归属于少数股东的综合收益总额 | -2,582,940.16 | -13,372,238.83 | -280,737.13 | 3,698,447 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-31 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |